The approval has been secured in partnership with Yabao Pharmaceuticals, a major player in China’s paediatric medicine segment
Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
Q4FY26 revenue climbs 19% to Rs. 2,290 crore as CDMO sterile injectables, radiopharma and generics businesses drive growth momentum
Company’s EBITDA grew 29.3 per cent to Rs. 290.4 crore, while PAT rose 36.4 per cent to Rs. 137.7 crore
US federal jury finds Japanese drugmaker liable for anticompetitive agreement delaying generic version of constipation drug Amitiza
Combined platform with 55+ centres aims to expand integrated maternity, fertility, neonatal and paediatric care across India
The event is expected to attract more than 100 senior professionals from pharmaceutical companies, CROs, regulatory agencies, and technology organisations
Eris Lifesciences posts sharp profit surge in FY26 driven by strong diabetes portfolio growth
SERB has a substantial European commercial presence and a successful track record in critical care and rare disease commercialization
Solutions designed to help clinicians reduce administrative burden, improve diagnostic accuracy, and spend more time with patients
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
